Rasburicase
Rasburicase (Elitek) is an enzyme infusion that rapidly dissolves the uric acid released when large numbers of leukaemia or lymphoma cells die at the start of treatment, protecting the kidneys from tumour lysis syndrome.
Overview
Rasburicase was approved by the FDA in July 2002 for initial management of plasma uric acid in children (adults added 2009) with leukaemia, lymphoma or solid tumours receiving therapy expected to cause tumour lysis, on randomised trials against allopurinol in which uric acid normalised within four hours in almost all patients; the EU authorised Fasturtec in 2001. It is standard for high-risk tumour lysis syndrome (Burkitt lymphoma, high-count ALL and AML, venetoclax ramp-up in CLL with bulky disease), often as a single dose rather than the labelled five days. Haemolysis and methaemoglobinaemia in G6PD deficiency, anaphylaxis and interference with uric acid assays (samples must be chilled) carry boxed warnings.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2002 | Initial management of plasma uric acid in paediatric patients with leukaemia, lymphoma or solid tumours at risk of tumour lysis (adults added 2009) |
| EU | 2001 | Treatment and prophylaxis of acute hyperuricaemia in haematological malignancy with high tumour burden (Fasturtec) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Rasburicase" OR ABSTRACT:"Rasburicase" OR TITLE:"Elitek" OR ABSTRACT:"Elitek" OR TITLE:"Fasturtec" OR ABSTRACT:"Fasturtec" OR TITLE:"Recombinant urate oxidase" OR ABSTRACT:"Recombinant urate oxidase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rasburicase, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductPlerixafor
Shares Sanofi, Diffuse large B-cell lymphoma and the tags nci-list, supportive.
- ProductClofarabine
Shares Sanofi, Acute lymphoblastic leukaemia and the tag nci-list.
- ProductDexrazoxane
Shares Acute lymphoblastic leukaemia and the tags nci-list, supportive.
- ProductPrednisone
Shares Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma and the tags nci-list, supportive.
- ProductPalifermin
Shares Diffuse large B-cell lymphoma and the tags nci-list, supportive.
- ProductAlemtuzumab
Shares Sanofi, Chronic lymphocytic leukaemia and the tag nci-list.
- ProductAmifostine
Shares the tags nci-list, supportive.
- ProductAprepitant (and fosaprepitant)
Shares the tags nci-list, supportive.